Brussels, Belgium, July 1, 2024

Merodis, an independent corporate finance advisory firm, is pleased to announce it has successfully advised the shareholders of Laboratoires Trenker on the sale to Belgian-based family company Erudite.Health. Laboratoires Trenker is a frontrunner in the Belux OTC pharma market through a proprietary branded portfolio of top-tier food supplements and medicines. Following the competitive auction process run by Merodis, Laboratoires Trenker has found with Erudite.Health a perfect fit regarding strategy, culture and ambitioned market expansion which also ensures that Trenker’s rich heritage as a 3rd generation family-owned company remains strongly anchored in Belgium. For Erudite.Health, Laboratoires Trenker ornaments the cornerstone of its pharmaceutical group, offering a platform for internationalization and accelerating its mission to transform personalized healthcare. The selling shareholders, Rodolphe and Pascale Trenker, will stay invested in the Company alongside its new owners.

Laboratoires Trenker (www.trenker.be) is a leading Belgian OTC/OTX pharmaceutical company. The company employs 90+ persons and currently generates EUR 28m in sales. Founded in 1933, Trenker has an extensive legacy as an innovative laboratory creating market-leading branded food supplement products such as Alline, Biocondil, Mobilityl, NC2 and Imutis. The company develops and manufactures most of its high-quality food supplements and medicines in its proprietary state-of-the-art production facility that complies with the strictest European production regulations for medicines (GMP) and food supplements (HACCP).

Erudite.Health (https://erudite.health/) is a Belgian-based family company, founded by Charles and Louis Declerck, aiming to redefine healthcare with comprehensive, evidence-based practices that prioritize patient involvement and well-being. Erudite.Health is divided into three pillars: Erudite.Healthtech, Erudite.Pharma, and Erudite.Therapeutics. This strategy integrates advanced OTC/OTX products, AI, and innovative pharmaceuticals. The company’s team combines in-depth knowledge in the medical and pharmaceutical fields with scientific rigor and validation in its healthcare approach, ensuring patient-centric care from diagnosis through treatment and beyond.

For more information, please contact:

Dirk Marckx
dma@merodis.com, +32 495 38 17 81
Fabian D’Hoore
fdh@merodis.com, +32 497 38 29 01